Sargramostim for active Crohn's disease.

BACKGROUND Sargramostim, granulocyte-macrophage colony-stimulating factor, a hematopoietic growth factor, stimulates cells of the intestinal innate immune system. Preliminary studies suggest sargramostim may have activity in Crohn's disease. To evaluate this novel therapeutic approach, we conducted a randomized, placebo-controlled trial. METHODS Using a 2:1 ratio, we randomly assigned 124 patients with moderate-to-severe active Crohn's disease to receive 6 mug of sargramostim per kilogram per day or placebo subcutaneously for 56 days. Antibiotics and aminosalicylates were allowed; immunosuppressants and glucocorticoids were prohibited. The primary end point was a clinical response, defined by a decrease from baseline of at least 70 points in the Crohn's Disease Activity Index (CDAI) at the end of treatment (day 57). Other end points included changes in disease severity and the health-related quality of life and adverse events. RESULTS There was no significant difference in the rate of the primary end point of a clinical response defined by a decrease of at least 70 points in the CDAI score on day 57 between the sargramostim and placebo groups (54 percent vs. 44 percent, P=0.28). However, significantly more patients in the sargramostim group than in the placebo group reached the secondary end points of a clinical response defined by a decrease from baseline of at least 100 points in the CDAI score on day 57 (48 percent vs. 26 percent, P=0.01) and of remission, defined by a CDAI score of 150 points or less on day 57 (40 percent vs. 19 percent, P=0.01). The rates of either type of clinical response and of remission were significantly higher in the sargramostim group than in the placebo group on day 29 of treatment and 30 days after treatment. The sargramostim group also had significant improvements in the quality of life. Mild-to-moderate injection-site reactions and bone pain were more common in the sargramostim group, and three patients in this group had serious adverse events possibly or probably related to treatment. CONCLUSIONS This study was negative for the primary end point, but findings for the secondary end points suggest that sargramostim therapy decreased disease severity and improved the quality of life in patients with active Crohn's disease.

[1]  A. Griffiths,et al.  Neutrophil dysfunction in glycogen storage disease Ib: association with Crohn's-like colitis. , 1991, Gastroenterology.

[2]  W. Reinisch,et al.  Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? , 2004, Gut.

[3]  K. Miyazono,et al.  Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. , 1989, Blood.

[4]  J Y Mary,et al.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.

[5]  S. Davies,et al.  Crohn's disease and the NOD2 gene: a role for paneth cells. , 2003, Gastroenterology.

[6]  J. Viney,et al.  GM-CSF treatment for Crohn's disease: a stimulating new therapy? , 2002, Current opinion in investigational drugs.

[7]  C. Barlow,et al.  Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Bechara,et al.  Granulocyte/macrophage colony-stimulating factor treatment improves alveolar epithelial barrier function in alcoholic rat lung. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[9]  B. Williams,et al.  Colony-stimulating factor-1 promotes clonogenic growth of normal murine colonic crypt epithelial cells in vitro. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[10]  R. Beart,et al.  Vascular complications of inflammatory bowel disease. , 1986, Mayo Clinic proceedings.

[11]  H. Seno,et al.  Identification of GM-CSF in Paneth cells using single-cell RT-PCR. , 2003, Biochemical and biophysical research communications.

[12]  J. Armitage.  Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor , 1998 .

[13]  D. Podolsky,et al.  CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. , 2003, Gastroenterology.

[14]  J. Rochon,et al.  Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.

[15]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[16]  L. Melton,et al.  Concurrence of inflammatory bowel disease and multiple sclerosis. , 2000, Mayo Clinic proceedings.

[17]  Judy H. Cho,et al.  Expression of NOD2 in Paneth cells: a possible link to Crohn’s ileitis , 2003, Gut.

[18]  E. Fikrig,et al.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Foster,et al.  Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2 , 2003, The Journal of Biological Chemistry.

[20]  W. Best,et al.  Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). , 1979, Gastroenterology.

[21]  J. Korzenik,et al.  Is Crohn's Disease an Immunodeficiency? , 2000, Digestive Diseases and Sciences.

[22]  M. Chamaillard,et al.  Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection* , 2003, The Journal of Biological Chemistry.

[23]  J. Korzenik,et al.  Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor , 2002, The Lancet.

[24]  Judy H. Cho,et al.  [Letters to Nature] , 1975, Nature.

[25]  J. Korzenik,et al.  Association of glycogen storage disease 1b and Crohn disease: results of a North American survey , 2007, European Journal of Pediatrics.

[26]  A. Tünger,et al.  Effect of granulocyte-macrophage colony stimulating factor on bacterial translocation after experimental obstructive jaundice. , 2001, The European journal of surgery = Acta chirurgica.

[27]  J. Gordon,et al.  Inflammatory Bowel Disease and Adenomas in Mice Expressing a Dominant Negative N-Cadherin , 1995, Science.